Lumicks, AstraZeneca and University of Cambridge create new drug discovery and biology center

As part of the collaboration, a C-Trap optical tweezers–fluorescence microscope has been installed at the University of Cambridge and will be used by AstraZeneca, University of Cambridge research groups and LUMICKS, to provide new insights in biology and early-stage drug discovery research.

LUMICKS’ technology allows for analysis of complex dynamic details related to the behavior and interaction of single molecules, allowing the center to investigate both the fundamental cause of diseases and potential for drug optimization.

This collaboration aims to generate data that will validate the use of dynamic single-molecule technology for biomedical and pharmaceutical research and potential applications for accelerating drug discovery.

LUMICKS CEO Olivier Heyning said: “Establishing the first ever Center of Excellence in Cambridge is an important step in introducing the power of dynamic single-molecule analysis to the biomedical and pharmaceutical research communities.

“Our tools enable scientists and pharmacologists to analyse the mechanistic details of processes underlying health and disease, with or without a small molecule drug lead being identified. This paves the way for the design of novel, more efficient strategies for highly-targeted drug discovery, and the selection of higher quality drug leads.”

AstraZeneca discovery sciences principal scientist Geoffrey Holdgate said: “C-Trap is a unique and powerful tool that could help us unravel precise molecular mechanisms of diseases and the mode of action of lead compounds.

“We are excited to be the first pharmaceutical company to use this technology and look forward to working with LUMICKS to validate the potential of single molecule analysis to enhance the drug discovery process.”

University of Cambridge biochemistry department professor Luca Pellegrini said: “This is a great opportunity for researchers across the University to explore complex molecular interactions and gain access to novel dynamic single molecule information regarding the workings of important biomolecular processes, especially in relation to the origin of diseases.”

In addition to installing the C-Trap system, LUMICKS will provide on-site support to center participants, as well as an application scientist who will work with the participants to create standardized and robust single-molecule analysis workflows.

Source: Company Press Release